[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Citations 0
This Week in JAMA
May 11, 2005

This Week in JAMA

JAMA. 2005;293(18):2187. doi:10.1001/jama.293.18.2187
Pediatric HIV Infection Treatment and Trends

Pediatric human immunodeficiency virus (HIV) infection is the subject of 2 articles in this issue of JAMA. Brogly and colleaguesArticle examined pediatric HIV treatment from 1987 through 2003 and assessed concordance with expert guidelines. They found a short lag time between identification of novel therapies and their use in children and that treatment was consistent with expert guidelines in 78% of cases. Switching to a new regimen was associated with failure to use guideline-recommended therapy. In a second article, Berk and colleaguesArticle examined disease progression and survival in a cohort of children with perinatal HIV infection in relation to year of birth and use of antiretroviral therapy (ART). They found less disease progression and improved survival at 3 years in children treated with ART compared with those who were not and in children treated in the first few months of age vs later. Recency of birth and more advanced therapy were associated with improved survival. In an editorial, YogevArticle discusses the benefits and risks of ART in children.

Follow-up of Elevated Screening Lead Levels

Prompt follow-up testing of children with abnormal screening blood levels is recommended, but estimates of the number of children who receive follow-up testing and factors associated with failure to do so are lacking. Kemper and colleaguesArticle reviewed Medicaid program files for children with documented elevated screening blood levels to assess the proportion of children with follow-up testing. They found only 53.9% of children with an elevated screening lead level had a follow-up test. Factors associated with a lower likelihood of follow-up were nonwhite race/ethnicity and living in urban, high-risk lead exposure areas. In an editorial, LanphearArticle outlines the shortcomings of current childhood lead poisoning prevention efforts.

Test Characteristics of Phonocardiographic S

Presence of the third (S3) and fourth (S4) heart sounds on phonocardiography has been considered a marker for left ventricular dysfunction, but whether phonocardiographic S3 and S4 correlate with objective markers of left ventricular function is not clear. In a prospective study of patients having left-sided heart catheterization, Marcus and colleagues found that absence of a phonocardiographic S3 or S4 was insufficient evidence to exclude ventricular dysfunction and, if present, S3 was superior to S4 in identifying patients with left ventricular dysfunction.

See Article

Modifying a Genetic Risk for Myocardial Infarction

Hakonarson and colleaguesArticle previously identified a variant in the gene encoding the 5-lipoxygenase–activating protein (FLAP), which is associated with an increased risk of myocardial infarction (MI). In this issue of JAMA they report results of a randomized clinical trial involving patients with variants of the FLAP gene or another gene in the leukotriene pathway, which assessed the effect of a FLAP inhibitor, DG-031, on biomarkers associated with MI risk. They found that DG-031 produced significant and dose-dependent suppression of biomarkers associated with arterial inflammation and MI. In an editorial, O’DonnellArticle discusses both the promise and limitations of these findings for MI risk modification.

A Piece of My Mind

“This is what I do for my patients. There is no billing code for this, no extra modifier that captures the history we have together.” From “Satisfaction?”

See Article

Medical News & Perspectives

Researchers have identified particular gene variants that may help explain the wide variation in the doses of common antiepileptic drugs required to prevent individual patients’ seizures.

See Article

Vitamin D and Fracture Risk

Meta-analysis of clinical trial data reveals that 700 to 800 IU/d of vitamin D reduces fracture risk in older adults.

See Article

Clinician’s corner

Achieving optimal symptom palliation and supporting family members when a patient is in the final days of life.

See Article

JAMA Patient Page

For your patients: Information about lead poisoning.

See Article